Related Experiment Video
Updated: Jun 13, 2025
13:05
Micropatterning and Assembly of 3D Microvessels
Published on: September 9, 2016
11.7K
An In Situ Curing, Shear-Responsive Biomaterial Designed for Durable Embolization of Microvasculature
Quynh P Pham1, Jeffrey V Groom1, Chander Sadasivan2
1Arsenal Medical, Inc, 100 Beaver Street, Suite 302, Waltham, MA, 02453, USA.
Advanced Healthcare Materials
|March 11, 2025
Summary
NeoCast, a novel biomaterial, offers superior microvascular occlusion via endovascular embolization. This solvent-free agent achieves consistent distal penetration and durable occlusion, outperforming current embolic agents.
Area of Science:
- Biomaterials Science
- Interventional Radiology
- Vascular Surgery
Background:
- Endovascular embolization aims to occlude pathological vessels using embolic agents.
- Current agents have limitations in distal penetration, reflux, and usability.
- Achieving microvascular occlusion is crucial for effective devascularization.
Purpose of the Study:
- To evaluate NeoCast, a novel liquid embolic agent, for its embolization performance.
- To compare NeoCast's microvascular occlusion capabilities against existing agents.
- To assess NeoCast's safety profile, including inflammation and neurotoxicity.
Main Methods:
- NeoCast, a polydimethylsiloxane-based biomaterial, was tested in preclinical arterial and venous models.
- Embolization was performed with and without flow arrest using standard microcatheters.
- Performance was assessed based on distal penetration, occlusion durability, fluoroscopic visibility, and biocompatibility.
Main Results:
- NeoCast demonstrated reproducible and superior distal penetration to the microvasculature.
- The agent provided durable occlusion with excellent fluoroscopic visibility.
- Mild inflammation was observed, with no evidence of neurotoxicity in brain tissue implantation.
Conclusions:
- NeoCast is a next-generation liquid embolic agent engineered for enhanced microvascular occlusion.
- Its shear-responsive properties and solvent-free composition address limitations of current embolic agents.
- NeoCast shows significant promise for applications requiring precise, distal embolization.
